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. INTRODUCTION AND LITERATURE REVIEW 
1.1 Vascular complications of diabetes mellitus 
The long term complications of diabetes mellitus fall in two groups: 
Microvascular complications that are nephropathy, neuropathy and 
retinopathy, and macrovascular disease that related to 
atherosclerosis, this occurs in both types 1 and 2 DM. The 
prevalence of all these complications increases with poor glycaemic 
control and duration of disease. [1]The central pathological 
mechanism in macrovascular disease is the process of 
atherosclerosis, which leads to narrowing of arterial walls 
throughout the body. Atherosclerosis is thought to result from 
chronic inflammation and injury to the arterial wall in the peripheral 
or coronary vascular system. In response to endothelial injury and 
inflammation, oxidized lipids from LDL particles accumulate in the 
endothelial wall of arteries. Angiotensin II may promote the 
oxidation of such particles. Monocytes then infiltrate the arterial 
wall and differentiate into macrophages, which accumulate oxidized 
lipids to form foam cells. Once formed, foam cells stimulate 
macrophage proliferation and attraction of T-lymphocytes. T-
lymphocytes, in turn, induce smooth muscle proliferation in the 
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arterial walls and collagen accumulation. The net result of the 
process is the formation of a lipid-rich atherosclerotic lesion with a 
fibrous cap. Rupture of this lesion leads to acute vascular 
infarction.(2) In addition to atheroma formation, there is strong 
evidence of increased platelet adhesion and hypercoagulability in 
type 2 diabetes. Impaired nitric oxide generation and increased free 
radical formation in platelets, as well as altered calcium regulation, 
may promote platelet aggregation. Elevated levels of plasminogen 
activator inhibitor type 1 may also impair fibrinolysis in patients 
with diabetes. The combination of increased coagulability and 
impaired fibrinolysis likely further increases the risk of vascular 
occlusion and cardiovascular events in type 2 diabetes.(3) 
The increased predisposition to atherosclerosis is multifactorial. 
Insulin has amajor role in the fat metabolism, and both type 1 and 2 
DM are associated with abnormal plasma levels of lipids. [1] In type 
1 DM, at presentation, or if glycaemic control deteriorates, marked 
hypertriglyceridaemia (manifests as an increase in very low density 
lipoprotein (VLDL), and often by chylomicronaemia is often present 
as a result of decreased activity of  lipoprotein lipase (which insulin 
stimulates) and increased activity of  hormone sensitive lipase 
(which insulin inhibits) leading to increased influx of free fatty acids 
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from adipose tissue that act as substrate of hepatic triglyceride 
synthesis. [1] Both effects are reversed by insulin treatment. [1]  
Indeed the degree of hypertriglyceridaemia correlates well with the 
degree of glycaemic control. Low density lipoprotein (LDL) 
concentration can also be increased, and that of high density 
lipoprotein decreased. [1]  
In type 2 DM hypertriglyceridaemia is also common, although it is 
not usually severe as in uncontrolled type 1 unless there is an 
additional genetic predisposition; it is due, mainly, to increased 
hepatic synthesis. [1]  
The VLDL contains increased triglyceride and cholysterol ester in 
relation to amount of apoprotein and although LDL concentration is 
not much increased. The particles tend to smaller, denser, and more 
atherogenic. As in type 1, HDL concentration is often decreased. [1] 
In both types glycation of apolipoprotein B may enhance 
atherogencity of LDL by reducing its affinity for the LDL receptors, 
so leading to increased uptake by macrophage scavenger receptors. 
[1] 
Other factors are implicated in the increased predisposition to 
atherosclerosis includes endothelial dysfunction and increased 
oxidative stress. [1] 
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1.2 Peripheral arterial disease: 
1.2.1Definition: 
 Peripheral arterial disease (PAD) comprises those entities which 
result in obstruction to blood flow in the arteries, exclusive of the 
coronary and intracranial vessels. [4] Although the definition of PAD 
technically includes problems within the extracranial carotid 
circulation, the upper extremity arteries, and the mesenteric and 
renal circulation, we will focus on chronic arterial occlusive disease 
in the arteries to the legs. Intermittent claudication, defined as pain 
in the muscles of the leg with ambulation, is the earliest and the 
most frequent presenting symptom in patients with lower extremity 
PAD. As the disease progresses in severity patients might have pain 
at rest, most prominent while the legs are elevated in bed at night, 
and relieved by dependency. Although claudication symptoms are 
typically localised in the calf or the thigh, “rest pain” is 
characteristically in the foot. In the late stages of PAD, tissue 
hypoperfusion progresses to ischaemic ulceration and gangrene, and 
major amputation is eventually required in more than a third of these 
patients. [4]     Importantly, mortality is closely linked with the 
presence of rest pain or tissue loss, so-called “critical limb 
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ischaemia” (CLI), with a 1-year mortality rate of about 20% in 
several series [5,6] 
1.2.2 Epidemiology 
Intermittent claudication has been used as a marker of PAD in 
epidemiological studies to approximate the frequency of lower 
extremity PAD in a particular patient population. The estimate is 
dependent, however, on demographic factors of the specific 
population under study, including age, sex, and geographic area. In 
addition, the methods used to determine the frequency of 
intermittent claudication affects the estimate.[7] For instance, studies 
based on questionnaires tend to overestimate the frequency of PAD 
with symptoms; patients with complaints that resemble claudication 
but are unrelated to the vascular system will be erroneously 
classified as having PAD. Studies that use an objective method of 
diagnosis, such as measurement of doppler systolic ankle pressures, 
are most accurate. An “ankle-brachial index” (ABI) can be 
calculated by dividing the ankle systolic pressure measured with a 
blood pressure at the malleolar level by the higher of the two 
brachial pressures. Defining PAD by an ankle-brachial index of less 
than 0·95, a frequency of 6·9% was observed in patients aged 45-74 
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years, only 22% of whom had symptoms. [8] The frequency of 
intermittent claudication increases dramatically with advancing age, 
ranging from 0·6% in individuals aged 45-54 years, to 2·5% in those 
aged 55-64 years, to 8·8% in patients aged 65-74 years. [9]  The 
Rotterdam study, a population-based analysis of 7715 patients, 
documented a frequency of intermittent claudication ranging from 
about 1% in those between the ages of 55-60 years to 4·6% in those 
between the ages of 80 and 85 years. [10] Despite this rather low 
frequency of intermittent claudication, 16·9% of men and 20·5% of 
women aged 55 and older had PAD as defined by an ankle-brachial 
index of less than 0·90 in either leg. This observation confirms that 
most patients with significant PAD are symptom-free. Although the 
diagnosis of symptomless PAD has less clinical significance with 
respect to the lower extremities, it is a strong marker for future 
cardiovascular events such as myocardial infarction. [11] 
The duration of DM correlate well with incidence and the extent of 
PAD.[12] in prospective cohort study, Al.Delaimy et al [13] found a 
strong positive association between the duration of DM and the risk 
of developing PAD. The association was particularly strongly 
positive among men with hypertension or who were current 
smokers. Alder et al [14] estimated the prevalence of PAD after 18 
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years of DM in 4,987 subjects (the United Kingdom prospective 
diabetes study) the data showed a high prevalence of PAD on those 
with longer duration of DM, the degree of glycaemic control is 
independent factor, the risk of PAD is associated with advancing age 
and presence of peripheral neuropathy. [15] 
Locally, M N Elbagir et al, found that the prevalence of 
microvascular complications was retinopathy 43%, nephropathy 
22% and neuropathy 37%. For macrovascular complications the 
prevalence was cardiovascular disease 28%, peripheral vascular 
disease 10% and cerebrovascular accidents 5.5%. [16]   
   
1.2.3 Risk factors: 
A variety of risk factors has been identified for peripheral arterial 
occlusive disease; risk factors that are almost identical to those of 
atherosclerotic disease elsewhere. The most important of these are 
age and sex; atherosclerosis of the lower extremities is more 
common in elderly individuals and in men. Diabetes mellitus is a 
most important risk factor for large vessel atherosclerotic occlusive 
disease. Smoking is also closely linked to PAD, a relation first 
identified by Erb in 1911, when the risk of intermittent claudication 
was reported to be three times greater in smokers. [17] The risk of 
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PAD was documented to be twice that in smokers compared with 
non-smokers in the Framingham study. [18] The increased risk seems 
correlated with the number of cigarettes smoked, [19] cessation of 
smoking has been associated with a rapid decrease in the risk for 
intermittent claudication. [20, 21] 
Hypertension has been linked with an increased risk of peripheral 
arterial occlusive disease in some studies. The Framingham data 
documented a 2·5-fold increase in the risk of PAD in men with 
hypertension and a 3·9-fold increase in women with hypertension. 
[18] Hyperlipidaemia has been associated with an increased rate of 
lower extremity occlusive disease. Although some studies have 
documented total cholesterol concentration as an important 
independent risk factor, [22, 23] others have suggested that the ratio of 
high density to total cholesterol is perhaps a better predictor. [24] 
Hypertriglyceridaemia [25] and lipoprotein (a) [26] have been shown 
to be independently associated with lower extremity PAD. 
Homocystine has also been implicated in atherogenesis; 
hyperhomocysteinaemia can be shown in 30% of patients with 
premature PAD. [27] There is a more substantial relation between 
hyperhomocysteinaemia and peripheral atherosclerosis compared 
with atherosclerosis in the coronary bed (odds ratio 6·8 vs 1·6, 
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respectively). And an increased fibrinogen concentration[28]  and an 
increased haematocrit [29]  have been associated with an increased 
risk of peripheral atherosclerosis. 
1.2.4 pathophysiology: 
 The pathogenesis of lower extremity PAD is best considered 
through a study of atherogenesis in general. Atherogenesis is most 
efficiently described through consideration of three stages, initiation 
of the lesion, progression of the lesion, and plaque complications.[30] 
The first stage involves the recruitment of mononuclear leucocytes 
to the intimal layer of the vessel wall. This inflammatory process is 
dependent on at least two groups of adhesion molecules. The first 
group, the selectins, is involved in the transient deposition of 
leucocytes on the endothelium. Endothelial cells overlying the 
atheromatous lesions express P-selectin. The second group of 
leucocyte adhesion molecules comprises an assemblage of 
immunoglobulins that are responsible for more sustained adherence 
of the leucocytes to the endothelium. Most notable in this regard is 
vascular cell adhesion molecule-1 (VCAM-1), present on the 
endothelial cells and responsible for binding of monocytes and 
lymphocytes.[31] 
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After leucocyte adherence, chemoattractant chemokines potentiate 
migration of the cells this process.[32] In addition, perturbations in 
local haemodynamics have also been implicated in the potentiation 
of adhesion molecule expression.[33] Finally, expression of adhesion 
molecules important in early atherogenesis can be downregulated as 
well. Nitric oxide has been shown to reduce leucocyte adhesion to 
endothelium,(34)in addition to its vasodilator actions. At the 
transcriptional level, nitric oxide interferes with the nuclear factor-
kappa B signalling pathway, inhibiting VCAM-1 gene expression in 
endothelial cells. Normal laminar blood flow augments endothelial 
nitric oxide synthase, increasing local nitric oxide concentrations 
and potentiating its anti-inflammatory and vasodilator actions. By 
contrast, turbulent flow, for example, as occurs at sites of arterial 
branching, attenuates nitric-oxide-mediated anti-inflammatory 
activity. Once the leucocytes have migrated into the intima through 
diapedesis, they accumulate lipids and assume a foamy histologic 
appearance. These foam cells comprise the earliest grossly 
recognisable stage of atherogenesis, the fatty streak. Although the 
fatty streak is reversible, increasing accumulation of foam cells in 
the intima transforms the fatty streak into a more advanced plaque. 
The plaque becomes increasingly more fibrous as smooth muscle 
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cells accumulate within the lesion and elaborate extracellular 
macromolecules that form a fibrous matrix. Calcium accumulates in 
the progressing atheroma with vascular smooth muscle cell 
expression of proteins that are involved in osteogenesis. 
The third and final stage of atherogenesis, the formation of a 
complicated or “unstable” plaque, is initiated by exposure of 
subintimal thrombogenic substances to the blood stream. The blood 
is protected from the lipid-laden atherosclerotic core by a “fibrous 
cap” in an uncomplicated plaque. There are two characteristics that 
determine whether a plaque will be stable or unstable. The first 
variable is simply the thickness of the fibrous plaque.35 The second 
factor is the amount of collagen present in the fibrous cap. Systemic 
factors have been implicated as determinants of plaque stability.[30] 
Inflammation, mediated through the attraction of activated T cells to 
the atheroma, may inhibit smooth muscle cell synthesis of collagen, 
weakening the fibrous cap. The finding of T lymphocyte 
accumulation at sites of plaque rupture is circumstantial testimony to 
this hypothesis [36].  Metalloproteinases are produced and released by 
macrophages within the atheroma, digesting collagen fibrils of the 
fibrous cap. Similarly, elastin can be degraded by cathepsin S and K 
secreted by macrophages present within the plaque, as well as by 
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metalloproteinase [37].  Finally, a paucity of smooth muscle cells may 
occur by apoptosis, accentuated by inflammatory cytokines within 
the atheroma,36 further diminishing the potential to maintain the 
collagen component of the fibrous cap. Chlamydia pneumoniae has 
also been implicated as an aetiologic factor in atherosclerosis, with 
infection of the cellular components of arterial plaque [39].  Although 
such infection can be shown experimentally to be associated with an 
increased expression of procoagulant proteins and chemo attractant 
activity [40], the precise role of C pneumoniae remains undefined. 
Proaggregatory substances in the subintima are exposed when the 
fibrous cap is disrupted. Tissue factor is perhaps the most important 
subintimal element involved in initiation of the coagulation cascade. 
Platelets, however, play a most important role under the high shear-
rate conditions present in arteries. A monolayer of platelets adheres 
to subintimal collagen fibrils through glycoprotein Ia/IIa receptors 
present in the platelet membrane and to exposed von Willebrand 
factor through platelet membrane glycoprotein Ib receptors. Next, 
platelets undergo the release reaction, secreting a variety of 
antagonists including thrombin, serotonin, adenosine diphosphate, 
and thromboxane A2. As the platelets undergo structural changes, 
flattening and forming pseudopodia, increasing numbers of 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 
 
 
 
 
 
 
glycoprotein IIb/IIIa receptor molecules are activated on the platelet 
surface. Fibrinogen in the blood stream acts as a bridge between two 
platelets, binding to the glycoprotein IIb/IIIa receptors of adjacent 
platelets.   A matrix of platelets and fibrinogen molecules forms a 
platelet plug, which can progress in one of two ways. First, if the 
platelet clump is firmly attached to the vessel wall, it can continue to 
build in size until the lumen is completely obstructed with platelet-
rich thrombus. In other cases, however, the platelet clump may be 
less firmly attached to the wall or the blood flow may be rapid 
enough that shear forces detach the clump before it occludes the 
vessel. In these cases, platelet-rich emboli flow downstream to lodge 
in peripheral vessels and cause clinical events such as stroke, 
amaurosis fugax, and digital ischaemia. 
 
1.2.5 Pathophysiology in diabetics: 
The pathophysiology of PAD in the diabetic population is similar to 
that in the non-diabetic population. However, the distribution of 
peripheral atherosclerosis in patients with PAD and diabetes is often 
more distal than in patients without diabetes, and commonly 
involves the tibial vessels [41]. The abnormal metabolic state that 
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accompanies diabetes directly contributes to the development of 
atherosclerosis; proatherogenic changes include increases in vascular 
inflammation and alterations in multiple cell types [42].Inflammation 
is an established risk factor for the development of atherosclerosis. 
Elevated levels of C-reactive protein (CRP) are strongly associated 
with the development of PAD. Furthermore, CRP levels are 
abnormally elevated in patients with impaired glucose tolerance [43]. 
In addition to being a marker of atherosclerosis, elevated levels of 
CRP may also be a risk factor for PAD. C-reactive protein has 
procoagulant effects related to its ability to enhance expression of 
tissue factor [44]. C-reactive protein also inhibits endothelial cell 
nitric oxide (NO) synthase, resulting in abnormal regulation of 
vascular tone, and increases production of plasminogen activator 
inhibitor-1, which inhibits the formation of fibrinolytic plasmin from 
plasminogen [45].  
Most patients with diabetes and PAD demonstrate generalized 
endothelial cell dysfunction. In healthy vessels, endothelial cells 
synthesize NO, a potent vasodilator that inhibits platelet activation 
and vascular smooth muscle cell migration. Diabetes impairs NO-
mediated vasodilatation [46]. A number of mechanisms contribute to 
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the decreased bioavailability of endothelium-derived NO in diabetes, 
including hyperglycemia, excess free fatty acids, and insulin 
resistance [47,48]. The effects of endothelial cell dysfunction increase 
arterial susceptibility to atherosclerosis.  
In addition to reducing NO concentrations, diabetes increases the 
production of vasoconstrictors, such as endothelin-1, which increase 
vascular tone and vascular smooth muscle cell growth and 
migration. Diabetes also stimulates other atherogenic pathways in 
vascular smooth muscle cells. For example, hyperglycemia activates 
protein kinase C and nuclear factor kappa-B, increasing the 
production of reactive oxygen species that promote the formation of 
atherosclerotic lesions [49]. Vascular smooth muscle cells cultured 
from patients with diabetes demonstrate enhanced migration, an 
important step in the progression to advanced plaque formation [50]. 
These cells strengthen the atheroma, making it less likely to rupture 
and cause thrombosis. However, Fukumoto et al. [51] demonstrated 
that advanced plaques in diabetic individuals have fewer smooth 
muscle cells than healthy controls; it is believed that hyperglycemia-
induced lipid modifications regulate the apoptosis of vascular 
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smooth muscle cells in advanced atherosclerotic lesions, promoting 
plaque instability and precipitation of clinical events [52].  
Platelet aggregation is enhanced in diabetes. Elevated glucose levels 
activate protein kinase C, decrease production of platelet-derived 
NO, and increase oxidative stress. In diabetes, platelets also have 
increased expression of glycoprotein Ib and IIb/IIIa receptors, 
enhancing their thrombotic potential [44]. In addition to potentiating 
platelet aggregation, diabetes augments blood coagulability by 
increasing the expression of tissue factor and decreasing levels of 
anticoagulants, such as antithrombin III. Consequently, it is more 
likely that atherosclerotic plaque rupture will result in thrombus 
formation [53].  
Thus, alterations in metabolism in diabetes adversely affect multiple 
cell types within the vascular wall. The increased tendency towards 
coagulation, coupled with impaired fibrinolysis, contributes to the 
enhanced thrombotic potential characteristic of diabetes.  
1.2.6 Diagnosis of PAD: 
The main reasons to diagnose PAD in diabetic individuals are to 
initiate therapies that decrease the risk of atherothrombotic events, 
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improve quality of life, and decrease disability. A diagnosis of PAD 
indicates the presence of systemic atherosclerosis that confers 
additional cardiovascular risk to the patient with diabetes, and gives 
further impetus to aggressively manage vascular risk factors in this 
high-risk group. 
A thorough medical history and physical examination are of primary 
importance in evaluating a diabetic individual for the presence of 
PAD. Information about the onset and duration of symptoms, pain 
characteristics, and any alleviating factors is helpful. The clinical 
stage of symptomatic PAD can be classified using the Fontaine 
staging system [54]. Fontaine stage I represents those who have PAD 
but are asymptomatic; stages IIa and IIb include patients with mild 
and moderate-to-severe intermittent claudication, respectively; those 
with ischemic rest pain are classified in Fontaine stage III; and 
patients with distal ulceration and gangrene represent Fontaine stage 
IV.A typical history of claudication has a low sensitivity, but a high 
specificity for PAD [55]. Physical examination should include blood-
pressure measurement, palpation of peripheral pulses, and 
auscultation of pulses and bruits. Palpation of peripheral pulses 
should include an assessment of the femoral, popliteal, and pedal 
vessels [56]; pulses should be graded as absent, diminished, or 
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normal. The absence of both the dorsalis pedis pulse and the 
posterior tibial pulse strongly suggests the presence of PAD, but 
further diagnostic testing is required to confirm the diagnosis.  
1.2.6.1 ABI screening. 
Although physical examination provides important information, 
additional non-invasive testing is necessary to ensure the diagnosis. 
The ABI is a reproducible and reasonably accurate measurement for 
the detection of PAD. The ABI is defined as the ratio of the ankle 
systolic blood pressure divided by the brachial systolic blood 
pressure, and is normally between 1.00 and 1.40 [57]. In PAD, the 
ankle systolic blood pressure is less than the brachial systolic blood 
pressure, and the ABI is reduced to <1.00; PAD is defined as an ABI 
<0.90. Lower ABI values indicate more severe PAD and a higher 
risk of cardiovascular events. The ABI may be normal in some 
patients with mild arterial narrowing; treadmill exercise has been 
used in these cases to increase the sensitivity of the test. Patients 
with diabetes mellitus or renal failure may have calcific lower leg 
arteries, rendering them incompressible and causing a falsely raised 
ABI; in these cases a toe brachial pressure index can be measured 
and is more predictive of substantial arterial disease. [58] 
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The ABI is measured by placing the patient in a supine position for 
5min. Systolic blood pressure is measured in both arms, and the 
higher value is used as the denominator of the ABI. Systolic blood 
pressure is then measured in the dorsalis pedis and posterior tibial 
arteries by placing the cuff just above the ankle. The higher value is 
the numerator of the ABI in each limb.  
1.2.6.2The diagnostic criteria for PAD based on the ABI are 
interpreted as follows:  
1. Normal if 0.91-1.30 
2. Mild obstruction if 0.70-0.90 
3. Moderate obstruction if 0.40-0.69 
4. Severe obstruction if < 0.40 
5. Poorly compressible if > 1.30 
1.3 .C-reactive proteins: 
1.3.1Definition: 
C-reactive protein (CRP) is a protein found in the blood, the levels 
of which rise in response to inflammation (i.e. C-reactive protein is 
an acute-phase protein). Its physiological role is to bind to 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
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phosphocholine expressed on the surface of dead or dying cells (and 
some types of bacteria) in order to activate the complement system 
via the C1Q complex.[59] 
CRP is synthesized by the liver [60] in response to factors released by 
fat cells (adipocytes).[61] It is a member of the pentraxin family of 
proteins.[60] It is not related to C-peptide or protein C. C-reactive 
protein was the first pattern recognition receptor (PRR) to be 
identified.[62] 
CRP was so named because it was first discovered as a substance in 
the serum of patients with acute inflammation that reacted with the 
C- (capsular) polysaccharide of pneumococcus. 
Discovered by Tillett and Francis in 1930 [63], it was initially thought 
that CRP might be a pathogenic secretion as it was elevated in 
people with a variety of illnesses including cancer,[60] however, 
discovery of hepatic synthesis demonstrated that it is a native 
protein.[64] 
The CRP gene is located on the first chromosome (1q21-q23). CRP 
is a 224-residue protein [65] with a monomer molar mass of 25106 
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Da. The protein is an annular pentameric disc in shape and a 
member of the small pentraxins family. 
1.3.2Role of CRP in atherosclerosis: 
1.3.2.1 Complement activation: 
Activation of the classical pathway of the complement system is a 
well known and direct biological function of CRP [66]. In situ 
hybridization showed intense mRNA signals for CRP and 
complement component C4 in SMCs and macrophages present in 
the thickened intima of the lesion. CRP also co-localizes with C5-
C9, the membrane attack complex, of complement [67]. Activation of 
this membrane attack complex (MAC) is initiated by the direct 
binding of CRP to C1q, also present in the atherosclerotic lesion [68], 
and characterized by elevated levels of component C5a [69]. C5a 
itself exerts potent chemotactic and pro-inflammatory effects and its 
plasma levels have been associated with advanced atherosclerosis. 
1.3.2.2Interaction with cell receptor: 
CRP binds to several receptors on human monocytes; to FcR? IIa 
(CD32) with high affinity and to FcR? I (CD64) with lower 
affinity[70] increasing phagocytosis and the release of inflammatory 
cytokines [71]. The Fc receptors have been described to mediate the 
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effect of CRP on human endothelial cells [72]. FcR? IIa is known as 
the putative CRP receptor for leukocytes [73] and also has been found 
on bovine aortic endothelial cells [74]. The binding of CRP to a 
receptor suggests its capacity to induce a specific biological effect 
[75], such as direct involvement in cell-mediation and opsonization. 
The interaction of CRP with CD36, a scavenger receptor which is 
expressed by macrophages and is involved in uptake of low-density 
lipoprotein particles (LDL), demonstrates a direct role of CRP 
through its interference with the binding of LDL to CD36 [76].  
1.3.2.3 Thrombosis: 
Thrombosis contributes to the progression of the atherosclerotic 
lesion and to the precipitation of the cardiovascular event. Direct 
actions of CRP which contribute to the induction of a prothrombotic 
state may be the enhancement of the procoagulant activity [77,78] or 
the reduction of fibrinolysis [79,80]. CRP has been suggested to induce 
a prothrombotic state via induction of tissue factor expression in 
human monocytes [81,82], but only in the presence of and through 
direct interaction with other blood cells as T-lymphocytes, B-
lymphocytes and natural killer cells [83].  
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1.3.2.4 Cellular modulation, recruitment and activation: 
CRP appears to be involved in the infiltration of monocytes into the 
vessel wall and their subsequent development into foam cells. The 
deposition of CRP in the arterial wall precedes monocyte infiltration 
and direct involvement of CRP in recruitment of blood monocytes 
has been demonstrated in vitro, suggesting CRP to be chemotactic 
for human blood monocytes [84]. CRP also promotes MCP-1 
mediated chemotaxis through upregulation of CC chemokine 
receptor 2 expression in human monocytes [85].  
The effect of CRP on T-lymphocytes is indirect. T-lymphocytes are 
recruited to the atherosclerotic lesion as a result of the ongoing 
inflammatory process. Through the stimulation of cytokine 
production and secretion by macrophages, CRP exerts an indirect 
effect on T-lymphocytes present in the atherosclerotic lesion. CRP 
induces macrophages to express interleukin-12, which contributes to 
the development of CD4+ T-helper cells [86]. In turn, these cells 
express interferon-? , which is synergistic with CRP in the execution 
of many functions contributing to the pro-atherosclerotic phenotype. 
In contrast, during CRP induced activation of complement and 
opsonization of apoptotic cells, the actively phagocyting 
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macrophages reduce expression of IL-12 and thereby suppress T-
lymphocytes [87]. 
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JUSTIFICATION 
 Diabetes mellitus (DM) is regarded as one of the major non-
communicable diseases in Sudan. The poorly controlled DM is 
associated with long term macrovascular complications, namely 
atherosclerosis. Peripheral arterial disease (PAD) is a known sequel 
of athersclerosis and it is postulated that C-reactive protein is one of 
the factors which are involved in the pathogenesis of atherosclerosis 
and in turn the occurrence of PAD, so the aim of this study is to 
know the levels of this acute phase reactant protein in diabetic 
patients with and without peripheral arterial disease. To our 
knowledge no such work has been done in Sudan.       
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OBJECTIVES 
General objective: 
-To evaluate C-reactive protein in diabetic patients. 
Specific objectives: 
-To evaluate C-reactive protein in diabetic patients with peripheral 
arterial disease (PAD). 
-To relate CRP levels to duration of diabetes mellitus of the subjects 
studied. 
-To relate CRP levels to ages of the subjects studied.    
   
 
 
 
 
 
 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 
 
 
 
 
 
 
 METHODS AND PATIENTS 
Study design: Cross-sectional analytical study.  
Study area: Khartoum teaching hospital and Jabir Abu el-iz centre 
for diabetic patients. 
Study duration     : From 5\1-5\2\2011 
Study population: 
A number of 81 diabetic patients with the same age groups (middle 
age and elderly) and 35 subjects who are normal control were 
studied, 41 patients out of the subjects studied had peripheral arterial 
disease (based on clinical findings and data), other 40 are diabetic 
(based on clinical data registration and blood glucose levels All 
subjects studied are regular attendants of diabetic outpatient clinic 
for management and follow up. 
Inclusion criteria: Diabetic patients, type 1 and 2. 
Exclusion criteria: 
Patients with past history of IHD, arthritis or any chronic 
inflammatory condition were excluded. 
Tools: 
A questionnaire utilized to collect data. 
SPSS-12 package and Excel 2003 utilized to analyze data. 
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Methods: 
After approval, written informed consent was obtained from the 
study participants. A questionnaire utilized to collect data from the 
patients and control group.  
Sample collection: Blood samples drawn from the antecubetal veins 
of seated subjects with minimal tourniquet use, specimens were 
collected in plain container left for at least 1 hour duration, 
centrifuged, separated into sera and stored at -4 degree centigrade 
for one week. 
Quality control:  material was measured for each run of 24 patients 
using immunometric assay. 
Procedure: CRP levels analyzed in all samples by means of a solid 
phase sandwich method the principle of which is that; a membrane 
coated with CRP monoclonal antibodies, when the sample flaws 
through the membrane, CRPs are captured by the monoclonal 
antibodies. The color intensity is measured quantitatively with 
NycoCard readerII. 
Detection limits (5 mg\l -120 mg\l).  
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5(68LTS 
Table 1 showed the age and sex distribution in the diabetics and 
control group. In the diabetics who had PAD symptoms (n=41), a 
number of 27 (65%)  patients age more than 50 years old compared 
to 18 patients age (45%) in the non-PAD group (table2,3). In the 
PAD group of patients a number of 15 patients (36.5%) had duration 
of DM between 11-15 years compared to a number of 7 patients 
(17.5%) in the non-PAD group (table4). In the PAD group a number 
of 21 (51%) patients had high CRP levels (>10 mg\l) compared to 
15 (37%) patients in the non-PAD group (table 5). The number of 
patients who had mild CRP concentration elevation (<10mg\l-
<50mg\l) was 12 and 9 patients in the PAD and the non-PAD group 
respectively. (Table5). 
The mean CRP level in the control was 4.92mg\l compared to 12.06 
and 18.5 in the non-PAD and the PAD group respectively. P-value 
0.141 and 0.001 respectively (table 6). The mean age was 57.5, 49 
and 46.92 years in the PAD, the non-PAD and control group 
respectively. The mean duration of DM was 13.4 and 5.7 in the PAD 
and the non-PAD group respectively. (Table 6). 
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The correlation between CRP levels and duration of DM PAD was; 
r=.692 p-value 0.00 and the correlation between CRP levels and 
ages of PAD patients r= 0.551 p-value 0.002 respectively. (Figure 
1). 
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Table1: comparison of age and sex distribution in diabetics 
(including both PAD & non-PAD) and the control group.

diabetics Control group 
frequencyfrequency Age in yrs
12.345681037.14286 13 <=40  
32.098772631.4285711 40-50 
28.395062314.28751 551-60 
27.160492214.287515 61-70 
2.8571 1 >70 
10081100 35total 
sex 
56.790124651.42857 18 Male 
43.209883548.57143 17 Female 
10081100 35 total 


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Table2: age and sex distribution in the non PAD 


%NoAge in yrs
37.515<=40
17.5741-50
32. 51351-60
12.5561-70
100%40Total
Sex
52.521Male
47.519Female
100%40total



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Table3: age and sex distribution in the PAD 
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%NoAge in yrs
2.431<=40
31.701341-50
24. 301051-60
41.461761-70
100%41Total
Sex
60.9725Male
39.02416Female
100%41total
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Table4: Duration of DM (in years) in PAD and Non PAD 
patients; comparison. 
Non-PADPAD group 
%No of 
patients
%No of 
patients
Duration of 
DM in yrs
37.51519.518<=5
37.51512.256-10
17.5736.591511-15
7.5331.711316-20
4040100%41total
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Table5: CRP levels in mg\l in both PAD Non-PAD and the 
control group; comparison. 
 
Control groupNon-PADPAD group
%No
%
No of 
patients
% 

No of 
patients
CRP in 
mg\l
94.283362.52548.7820<=10
5.72222.5929.271210-50
0.0007.537.317351-90
0.0007.5314.636>90
100%351004010041total
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Table 6: means of CRP levels, age duration of DM in PAD non 
PAD and the control group: 
 
p-valueControl 
group
Non-PADPAD groupVariable
0.0334.2912.0618.5CRP in 
mg\l
-46.54957Age in yrs
0.001-5.713.5DM 
duration
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Fig 1: Pearson correlation between CRP levels and ages in PAD 
group; r=.551 p-value 0.002 
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Fig 2:  poorer correlation of CRP levels and ages of the non-
PAD patients. 
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 DISCUSSION 
 
CRP may be predictive of the risk of developing symptomatic 
peripheral arterial disease, but further studies are needed to confirm 
its clinical utility in this regard. Perhaps of greater clinical relevant 
is the fact that the circulating CRP levels appear to be predictive of 
cardiovascular events and mortality in patients with known 
peripheral arterial disease. 
           Inflammation is important for the initiation and progression 
of PAD, and the inflammatory mediators involved in this process are 
similar to those contributing to the development of coronary artery 
disease (CAD). There several candidate inflammatory triggers, 
including the traditional risk factors that exert a proatherogenic role 
at least in part, through an inflammatory mechanism. In 1998, Riker 
et al studied in prospective nested case control study carried out in 
apparently healthy men enrolled in the physician health study; found 
that the relative risk of developing PAD increased significantly with 
each increasing quartile of baseline CRP concentration, such that 
men in the highest quartile (>2.1 mg\l) had a two folds increased 
risk compared with men in the lowest quartile. 
        The results of the study showed a linear correlation between the 
ages of the patients and CRP levels in the peripheral arterial disease 
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group of patients regardless of sex of the patient, another study by 
Lugci Ferrucci et al (88) found that Age remained a significant 
predictor of higher CRP in women but not in men, on the other hand 
The results showed linear correlation between the levels of CRP 
levels and duration of DM in PAD group of patients, other studies 
found no correlation, Dana King [89] for example found poor 
correlation between CRP and durations of DM. from this results one 
might conclude that age is a significant predictor of higher CRP 
when compared to duration of DM  
Results of this cross sectional study reported higher levels of 
CRP in patients who had PAD symptoms in comparison to patients 
who had PAD symptoms. The results revealed a significant 
difference mean CRP level between patients and the control group. 
In the study the results also revealed a mean CRP level of PAD 
group equaling one fold and half in comparison to that of non PAD 
group. This demonstrates a comparable result to that of Joaquin De 
Haro et al in their study [90], who found that the mean values of CRP 
plasma levels were increased in association with higher clinical 
severity in patients with mild, moderate and severe PAD. Other 
study by Cassar et al(91) who studied 132 claudiants and 30 patients 
with critical limb ischemia found that high-sensitivity CRP levels in 
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patients with critical limb ischemia is more than that in claudicants 
by about two folds.  
One limitation of this study is that other proinflammatory markers 
related to the pathogenesis of athersclerosis like cytokine IL-6 and 
fibrinogen were not included, such variables in addition to 
lipoproteins namely LDL, triglyceride and HDL, if were included in 
the study one can conclude very sound and strong results. Another 
limitation, the study depends only on the clinical Data (symptoms 
and physical examination findings) rather than the ABI in 
diagnosing PAD.   
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4.2. CONCLUSION 
From this study the following conclusions are drawn: 
§ There is a linear correlation between CRP levels and ages of 
the peripheral arterial disease` patients. 
§ The mean CRP level in PAD group of patients is about one 
fold and half of that in non-PAD group of patients. 
§ There is a linear correlation between CRP levels and duration 
of DM in PAD group.   
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. RECOMMENDATIONS 
 I recommend utilizing CRP test in the follow up of diabetics with 
risk of PAD especially those above 50 years old and who had 
peripheral vascular symptoms. 
Larger studies should be conducted to assess the role CRP as a 
predictor of PAD in diabetics. 
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University of Khartoum 
Graduate college  
Medical & Health Studies Board 
  Thesis about: C-reactive protein in diabetics with and 
without peripheral arterial Disease. 
 
Data collection sheet 
Do you accept to participate in this study? 
Yes?                                                                No: ?  
Name: 
                                                                                                   
Age: 
                                                                                                    
Sex: 
Male: ?                      female: ?  
Type of DM: 
Type I: ?                                                        type II: ?  
Duration of DM: 
                                                                                                   
Lower limbs complaints:   
                                                                                                   
                                                                                                   
                                                                                                   
Any PH of amputation: 
Yes: ?                                                        No: ?  
Hypertension: 
Yes: ?                                                           No: ?  
IHD: 
Yes: ?                                                           No: ?  
 
Chronic joint disease: 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 
 
 
 
 
 
 
Yes: ?                                                             No: ?       
History of acute or chronic inflammation: 
Yes: ?                        No: ?  
If yes determine: 
                                                                                           
 
History of smoking: 
Yes: ?                        No: ?  
Any FH of DM, HTN or IHD: 
Yes: ?                        No: ?  
Drug history: 

Type of diabetes medication you use: 
Insulin: ?                      tablets: ?  
Use of long term Aspirin or other NSAID: 
Yes: ?                        No: ?  
Physical examination: 
 
Lower limb examination: 
 
Foot ulcer: 
Yes: ?                        No: ?  
Tenderness: 
Yes: ?                        No: ?  
 Pedal pulsation: 
Intact: ?                     weak: ?                  absent: ?  
                                                                                 evel:CRP l 
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ABI : Ankle Brachial Index. 
CLI : Critical Limb Ischaemia. 
CRP : C - reactive protein. 
DM : Diabetes Mellitus. 
eNO : Endothelial Nitric Oxide. 
HDL : High Density Lipoprotein. 
IHD : Ischaemic Heart Disease.    
LDL : Low Density Lipoprotein. 
NO : Nitric Oxide. 
PAD : Peripheral Arterial Disease (affecting legs). 
VCAM-ϭ : Vascular Cell Adhesion Molecule-ϭ͘ 
VLDL : Very Low Density Lipoprotein. 
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Abstract 
Background: C-reactive protein is a new emerging predictive marker of 
ischaemic heart diseases; it has been postulated that the substance has a 
role in the pathogenesis of peripheral arterial disease (PAD). 
Methods: This is a cross sectional descriptive study conducted at 
Khartoum teaching hospital & Jabir Abu Al-iz centre from 5\1\2011 to 
5\2\2011. The aim was to measure CRP levels in diabetics with and 
without PAD and to relate the concentration of CRP to duration of 
diabetes mellitus and ages of the patients. Study population (n=116) of 
whom 81 diabetics grouped into 41 diabetics with PAD symptoms and 40 
without PAD symptoms, other 35 subjects were normal control. A 
questionnaire was utilized to collect data, blood samples obtained, 
separated into sera and using immunometric assay CRP levels were 
measured at the same time for all patients 
Results: CRP levels were positively correlated with duration of DM and 
ages of the peripheral arterial disease diabetics ͕ƌсϬ͘ϲϵϮƉ-ǀĂůƵĞϬ͘ϬϬϬ 
ĂŶĚƌсϬ͘ϱϱϭƉ-ǀĂůƵĞсϬ͘ϬϬϮ respectively. PAD had higher CRP levels in 
comparison to non-PAD diabetics; mean CRP level is ϭϴ͘ϱ versus ϭϮ͘Ϭϲ
respectively p-ǀĂůƵĞсϬ͘Ϭϯϯ͘  
Conclusion: The linear correlation between CRP levels and duration of 
DM and ages of diabetics is stronger in PAD group of patients. The mean 
CRP level in PAD group equals one fold and half when compared to that 
of non PAD group.  
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